United Therapeutics (NASDAQ:UTHR) Price Target Raised to $350.00 at TD Cowen

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by equities research analysts at TD Cowen from $270.00 to $350.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price target indicates a potential upside of 6.30% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Oppenheimer lifted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $321.55.

United Therapeutics Trading Up 2.0 %

Shares of UTHR stock opened at $329.25 on Thursday. The firm has a 50 day moving average price of $287.54 and a two-hundred day moving average price of $248.48. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $14.61 billion, a PE ratio of 15.57, a price-to-earnings-growth ratio of 1.39 and a beta of 0.55. United Therapeutics has a 12-month low of $208.62 and a 12-month high of $329.93.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period last year, the business posted $4.86 earnings per share. As a group, analysts predict that United Therapeutics will post 24.73 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $313.25, for a total value of $1,127,700.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $40,722.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $313.25, for a total transaction of $1,127,700.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $40,722.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 100,884 shares of company stock valued at $27,604,643. 12.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC raised its holdings in shares of United Therapeutics by 13,769.2% during the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after purchasing an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in shares of United Therapeutics by 54.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after purchasing an additional 33,338 shares during the period. Nordea Investment Management AB raised its holdings in shares of United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after purchasing an additional 23,532 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of United Therapeutics by 90.3% during the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after purchasing an additional 26,325 shares during the period. Finally, Duality Advisers LP raised its holdings in shares of United Therapeutics by 56.1% during the fourth quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock valued at $3,440,000 after purchasing an additional 5,622 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.